Antibody-drug conjugates:design and clinical progress / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1209-2016.
Artículo
en Chino
| WPRIM
| ID: wpr-779298
ABSTRACT
Antibody-drug conjugates, constructed with monoclonal antibodies, linker and cytotoxins, have distinctive advantages over chemotherapy drugs and antibody drugs in cancer therapy. In this review, the strategy of developing ADCs, and the important progress in past decade are well summarized. The representative ADCs in the pipeline are introduced and characterized with their new features. While, perspective for future directions of ADCs is proposed.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Acta Pharmaceutica Sinica
Año:
2016
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS